1. Journal and Team Published in Trends in Biotechnology (a top journal in the field of bioengineering), jointly completed by teams from Xi'an Jiaotong University, Shanghai Jiao Tong University, Xidian University, and others.
2. Study Type Basic translational research, a multifunctional theranostic live bacterial platform integrating in vivo fluorescence imaging + photothermal therapy + gene therapy + immunotherapy, targeting breast cancer.
3. Technology Readiness Level Assessed as NASA TRL 3–4: validated in vitro and in mouse models; not yet advanced to large-animal or human clinical trials.

II. Research Background and Existing Pain Points

1. Advantages of Bacteria-Based Tumor Therapy

Engineered bacteria represent a promising live tumor therapeutic approach, offering three major advantages: easy genetic modification, natural immune adjuvant properties, and targeted tumor colonization. Most current studies modify photothermal agents on bacterial surfaces to achieve photothermal therapy.

2. Limitations of Existing Technologies

• Conventional photothermal therapy at high temperatures tends to damage normal tissues surrounding the tumor while also reducing bacterial viability;
• Bacterial gene therapy alone lacks spatiotemporal specificity, and systemic administration may cause off-target toxicity with limited therapeutic efficacy;
• Certain engineered strains (e.g., BL21) exhibit high pathogenicity and poor biosafety, with low carrier loading efficiency.

3. Proposed Solution of This Study

Leveraging the deep tissue penetration and precise controllability of near-infrared light (808 nm), a temperature-responsive genetic circuit was constructed: photothermal heating → activation of therapeutic gene expression, combined with a probiotic carrier to achieve precise, low-toxicity, multimodal synergistic antitumor therapy.

III. Core System Construction and Mechanism of Action

(I) Core Vector: EcN@ICG-CRE

1. Chassis Strain: Escherichia coli Nissle 1917 (EcN) A clinically recognized probiotic with no pathogenicity, inherent tumor-targeting capability, and the ability to act as an immune adjuvant to enhance antitumor immunity, with high biosafety.
2. Photothermal Agent: Indocyanine Green (ICG) + Polyethoxylated Castor Oil (CRE) ICG is a clinically approved near-infrared fluorescence/photothermal dual-functional reagent. It is loaded onto the EcN surface via simple co-incubation (no complex covalent modification or nanoparticle synthesis required), with an ICG loading efficiency of 27.50%. A 5% ICG-CRE formulation was selected as optimal (minimal impact on bacterial viability).
3. Functional Integration EcN@ICG-CRE combines two core functions: near-infrared fluorescence imaging (840–880 nm) and photothermal heat generation.

(II) Temperature-Controlled Genetic Circuit (Core Innovation)

EcN was transformed with the thermosensitive plasmid pBV220-ClyA:

1. The plasmid carries a temperature-sensitive repressor protein, TcI: at normal temperature (37°C), it binds to the promoter and suppresses the expression of cytolysin A (ClyA);
2. Near-infrared laser irradiation → ICG generates heat, raising local temperature above 42°C → TcI denatures and becomes inactivated → repression is relieved, leading to massive ClyA expression;
3. ClyA is a cytolytic toxin that can directly lyse tumor cells, achieving photothermal killing + genotoxin killing in synergy.

(III) Triple Antitumor Mechanisms (Integrated Synergy)

1. Photothermal Therapy (PTT): Under 808 nm laser irradiation, local tumor temperature can rise above 55°C, directly inducing thermal tumor cell death;
2. Gene Therapy: Heat shock activates ClyA expression, and the oncolytic toxin further kills tumor cells;
3. Immunotherapy: EcN acts as a natural immune adjuvant, recruiting T cells, B cells, and macrophages, upregulating antitumor cytokines such as IFN-γ and TNF-α, thereby activating systemic antitumor immunity.

IV. Key Experimental Results and Validation

1. Characterization of Engineered Bacteria (In Vitro)

• Morphology, zeta potential, and growth activity: After ICG-CRE loading, EcN maintained intact morphology with no significant decrease in activity, demonstrating good system stability;
• Optical properties: Exhibited characteristic ICG absorption peaks and near-infrared fluorescence, enabling in vivo localization and tracking;
• Photothermal performance: Positively correlated with laser power, bacterial concentration, and irradiation duration; capable of multiple photothermal cycles with bacterial viability >90%, showing excellent photothermal stability.

2. Feasibility Validation of Temperature-Controlled Genetic Circuit (EGFP Reporter)

Enhanced green fluorescent protein (EGFP) was used as a reporter in place of ClyA for tracing:

• Stable activation of gene expression was achieved at temperatures >42°C, with 45°C identified as the optimal therapeutic temperature (balancing bacterial viability and gene expression efficiency);
• Higher laser power/duration resulted in stronger fluorescence, demonstrating that photothermal stimulation can precisely and controllably activate downstream genes;
• In vivo validation in mice: Gene expression was localized exclusively to the tumor site, with no detectable signal in normal organs, demonstrating high spatial targeting specificity.

3. In Vitro Validation of ClyA Oncolytic Function

• Hemolysis assay: Higher temperatures and longer irradiation times led to increased ClyA expression and stronger hemolytic activity;
• Cell experiments (4T1 breast cancer cells): The combination group (EcN@ICG-CRE + laser) exhibited the lowest cell viability and highest apoptosis rate; laser alone showed no cytotoxicity, confirming that the killing effect is due to the synergistic action of photothermal therapy and ClyA;
• Comparison between wild-type EcN and ClyA-engineered strains directly demonstrated that ClyA is a key antitumor effector molecule.

4. In Vivo Antitumor Efficacy (Tumor-Bearing Mouse Model)

• Treatment regimen: Intratumoral injection + laser irradiation every 4 days, for a total of 21 days;
• Antitumor efficacy: Tumor volume in the combination group was significantly suppressed, with in vivo bioluminescence imaging visually confirming near-stagnant tumor growth;
• Biosafety: No abnormal body weight changes in mice; H&E staining of major organs (heart, liver, spleen, lung, kidney) showed no pathological damage; serum markers for liver and kidney function remained within normal ranges;
• Bacterial distribution: EcN was predominantly enriched in tumor tissues, with minimal colonization of normal organs, indicating low off-target risk.

5. Immunological and Molecular Mechanisms

1. Immune Activation Significant immune cell infiltration was detected in tumor tissues, and serum antitumor cytokines were markedly upregulated, confirming that EcN-mediated immune responses contribute to tumor suppression.
2. Transcriptomic and miRNA Regulatory Mechanisms 
   • Differentially expressed genes: A total of 1,813 DEGs were identified, enriched in pathways such as PPAR, neutrophil extracellular trap formation, and efferocytosis, leading to the induction of tumor cell apoptosis;
   • miRNA network: Upregulation of miR-5110, miR-528, and miR-5126 inhibited downstream target genes involved in migration promotion and anti-apoptosis, thereby blocking tumor invasion and metastasis while promoting cell death, revealing novel mechanisms at the non-coding RNA level.

V. Research Highlights and Innovations

1. Simple and Translational System ICG, a clinically approved reagent, is loaded solely via co-incubation, requiring no complex chemical modifications or nanoparticle synthesis — a straightforward process conducive to scale-up and clinical translation.
2. Precise Spatiotemporal Control Near-infrared laser enables remote temperature control, activating ClyA expression exclusively in laser-irradiated tumor regions without affecting normal tissues, thus overcoming the off-target toxicity issues associated with conventional gene therapy.
3. Quadruple-Modal Synergistic Therapy Integrating fluorescence imaging guidance + photothermal therapy + temperature-controlled gene therapy + probiotic immunotherapy, the multi-mechanism combination yields significantly superior antitumor efficacy compared to monotherapies.
4. High Safety of Chassis Strain The use of the commercial probiotic EcN, as opposed to pathogenic or engineered expression strains, poses lower in vivo risks and aligns with the safety requirements for live biotherapeutic products.
5. Comprehensive Mechanistic Dissection The study elucidates the therapeutic pathways from cellular, animal, protein, transcriptomic, and miRNA levels, providing molecular targets for further optimization.

VI. Current Challenges and Future Directions (Unresolved Issues Identified in the Paper)

1. Current Limitations

1. Temperature control challenges in deep-seated tumors: Current laser applications are suitable for subcutaneous tumors; precise temperature control for deep-tissue lesions remains difficult, with potential thermal damage to surrounding tissues;
2. Post-treatment bacterial clearance: Although EcN is a probiotic, residual persistence in vivo still poses a potential long-term infection risk;
3. Delivery route limitations: The current intratumoral injection approach is not applicable to carcinoma in situ or metastatic tumors;
4. Regulatory hurdles: As live biotherapeutic products, the production and safety evaluation regulatory frameworks differ from those of conventional drugs.

2. Optimization Strategies and Research Prospects

1. Integration of real-time temperature monitoring to dynamically adjust laser dosage and protect normal tissues;
2. Introduction of inducible suicide/lysis genetic circuits into EcN to actively eliminate residual bacteria after treatment;
3. Development of interventional, endoscopic, and other delivery modalities to extend application to deep-tissue and metastatic tumor models, along with large-animal preclinical toxicology and biodistribution studies;
4. Establishment of standardized production and safety evaluation systems for live biotherapeutic products to facilitate clinical translation.

VII. Overall Research Assessment

1. Academic Value: The study establishes a light-controlled engineered probiotic theranostic platform, offering a new paradigm for bacteria-based combination tumor therapy, while also uncovering miRNA-mediated mechanisms of tumor progression, thereby enriching the theoretical foundation of live biotherapeutics.
2. Translational Potential: The core materials (EcN, ICG) are already clinically available; the preparation process is simple and the in vivo safety profile is favorable. Compared with fully synthetic nanomedicines or pathogenic engineered bacteria, this approach holds greater feasibility for clinical translation.

Positioning: This represents a breakthrough preclinical fundamental study, currently validated only in mouse models. Clinical application still requires addressing the three major engineering challenges of delivery, bacterial clearance, and deep-tissue tumor treatment.

Article link: https://www.sciencedirect.com/science/article/pii/S0167779926002350?dgcid=author 

Products Used in This Study:

```